Overview
The analysis is based on the Council document ST 6367 2026 INIT, which is the final compromise text for the proposed Directive 2023/0132(COD) on the revision of the EU pharmaceutical legislation for human medicines. This is a major legislative file under the ordinary legislative procedure, currently ongoing. The initiative represents a comprehensive overhaul of the existing framework (Directive 2001/83/EC), aiming to modernise the rules governing medicinal products to address contemporary challenges in innovation, access, supply security, and environmental sustainability.
Legislative timeline
The legislative procedure began with the European Commission's proposal in 2023. The European Parliament (EP) referred the file to committee on 14 September 2023, with the committee report tabled on 3 October 2023. A series of committee opinions and amendments were tabled throughout November 2023. Key committee opinions were adopted in February 2024, and the lead committee adopted its report on 19 March 2024. The file was tabled for plenary and voted on 10 April 2024, where the Parliament adopted its position and amendments to the Commission's proposal. Since then, interinstitutional negotiations (trilogues) have been ongoing, with sessions recorded on 17 June 2025, 7 October 2025, and 11 November 2025. The next key step is a Council meeting scheduled for 3 June 2026, dedicated to the analysis of the final compromise text with a view to reaching a political agreement.
Institutional handling
The lead Directorate-General in the European Commission is DG SANTE (Health and Food Safety), under the responsibility of Commissioner Olivér Várhelyi. In the Council of the EU, the file is handled by the Environment Council configuration (ENV). In the European Parliament, the file was subject to committee scrutiny leading to a plenary vote that established its negotiating position for the trilogue discussions.
Stakeholder reactions
Stakeholder engagement on this file has been extensive, with 66 documented meetings held between stakeholders and EU policymakers. Of these, 57 were with Members of the European Parliament, 9 with European Commission staff, and none directly with Commissioners. These interactions involved 34 distinct organisations. The most frequently encountered organisations in these engagements include MEDICINES FOR EUROPE, Affordable Medicines Europe, the European Federation of Pharmaceutical Industries and Associations (EFPIA), and Novo Nordisk A/S, as well as individual advocate Silvia Marzot. The provided data on stakeholder positions, derived from meeting topic analyses, primarily pertains to financial regulation and sustainability criteria in investments. While these topics may relate to broader economic aspects of the pharmaceutical sector, the specific positions recorded—such as support from banking associations for regulatory simplification or Cleantech's advocacy for adjusted capital rules to favor investments in clean technologies—are not directly linked to the core pharmaceutical provisions described in the Council's final compromise text. Therefore, a detailed account of stakeholder views on the central elements of the pharmaceutical legislation revision, such as incentives, access, or environmental integration, cannot be provided based on the available data.
Media coverage
No data on media coverage is provided.